These data validated combined TOP1 and CHEK1 inhibition as a potent combination in MSS and KRAS–TP53 double-mutant colon cancer cells, and demonstrate the potential for follow-up of other synergistic drug combinations identified here. The gene discussed is TP53; the disease is colonic neoplasm.